1-12 of 12
Andrea Anichini
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era

Free
Michele Maio, Omid Hamid, James Larkin, Alessia Covre, Maresa Altomonte, Luana Calabrò, Santosh A. Vardhana, Caroline Robert, Ramy Ibrahim, Andrea Anichini, Jedd D. Wolchok, Anna Maria Di Giacomo
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (16): 4201–4205.
https://doi.org/10.1158/1078-0432.CCR-20-1657
Published: 14 August 2020
View article titled, Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era
Open the PDF for Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era in another window
Journal Articles

Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial

Free
Anna Maria Di Giacomo, Alessia Covre, Francesca Finotello, Dietmar Rieder, Riccardo Danielli, Luca Sigalotti, Diana Giannarelli, Florent Petitprez, Laetitia Lacroix, Monica Valente, Ornella Cutaia, Carolina Fazio, Giovanni Amato, Andrea Lazzeri, Santa Monterisi, Clelia Miracco, Sandra Coral, Andrea Anichini, Christoph Bock, Amelie Nemc, Aram Oganesian, James Lowder, Mohammad Azab, Wolf H. Fridman, Catherine Sautès-Fridman, Zlatko Trajanoski, Michele Maio
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (24): 7351–7362.
https://doi.org/10.1158/1078-0432.CCR-19-1335
Published: 13 December 2019
View article titled, Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial
Open the PDF for Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade

Free
Giuseppe Lo Russo, Massimo Moro, Michele Sommariva, Valeria Cancila, Mattia Boeri, Giovanni Centonze, Simona Ferro, Monica Ganzinelli, Patrizia Gasparini, Veronica Huber, Massimo Milione, Luca Porcu, Claudia Proto, Giancarlo Pruneri, Diego Signorelli, Sabina Sangaletti, Lucia Sfondrini, Chiara Storti, Elena Tassi, Alberto Bardelli, Silvia Marsoni, Valter Torri, Claudio Tripodo, Mario Paolo Colombo, Andrea Anichini, Licia Rivoltini, Andrea Balsari, Gabriella Sozzi, Marina Chiara Garassino
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (3): 989–999.
https://doi.org/10.1158/1078-0432.CCR-18-1390
Published: 01 February 2019
View article titled, Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade
Open the PDF for Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade in another window
Includes: Supplementary data
Journal Articles

Phase II Study of Perifosine and Sorafenib Dual-Targeted Therapy in Patients with Relapsed or Refractory Lymphoproliferative Diseases

Free
Anna Guidetti, Carmelo Carlo-Stella, Silvia L. Locatelli, Walter Malorni, Roberta Mortarini, Simonetta Viviani, Domenico Russo, Alfonso Marchianò, Roberto Sorasio, Anna Dodero, Lucia Farina, Laura Giordano, Massimo Di Nicola, Andrea Anichini, Paolo Corradini, Alessandro M. Gianni
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (22): 5641–5651.
https://doi.org/10.1158/1078-0432.CCR-14-0770
Published: 13 November 2014
View article titled, Phase II Study of Perifosine and Sorafenib Dual-Targeted Therapy in Patients with Relapsed or Refractory Lymphoproliferative Diseases
Open the PDF for Phase II Study of Perifosine and Sorafenib Dual-Targeted Therapy in Patients with Relapsed or Refractory Lymphoproliferative Diseases in another window
Includes: Supplementary data
Journal Articles

IGKV3 Proteins as Candidate “Off-the-Shelf” Vaccines for Kappa-Light Chain–Restricted B-Cell Non-Hodgkin Lymphomas

Free
Debora Martorelli, Massimo Guidoboni, Valli De Re, Elena Muraro, Riccardo Turrini, Anna Merlo, Elisa Pasini, Laura Caggiari, Luca Romagnoli, Michele Spina, Roberta Mortarini, Daniela Gasparotto, Mario Mazzucato, Antonino Carbone, Antonio Rosato, Andrea Anichini, Riccardo Dolcetti
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (15): 4080–4091.
https://doi.org/10.1158/1078-0432.CCR-12-0763
Published: 30 July 2012
View article titled, IGKV3 Proteins as Candidate “Off-the-Shelf” Vaccines for Kappa-Light Chain–Restricted B-Cell Non-Hodgkin Lymphomas
Open the PDF for IGKV3 Proteins as Candidate “Off-the-Shelf” Vaccines for Kappa-Light Chain–Restricted B-Cell Non-Hodgkin Lymphomas in another window
Includes: Supplementary data
Journal Articles

Role of Apollon in Human Melanoma Resistance to Antitumor Agents That Activate the Intrinsic or the Extrinsic Apoptosis Pathways

Free
Elena Tassi, Marina Zanon, Claudia Vegetti, Alessandra Molla, Ilaria Bersani, Valentina Perotti, Marzia Pennati, Nadia Zaffaroni, Michele Milella, Soldano Ferrone, Carmelo Carlo-Stella, Alessandro M. Gianni, Roberta Mortarini, Andrea Anichini
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (12): 3316–3327.
https://doi.org/10.1158/1078-0432.CCR-11-2232
Published: 14 June 2012
View article titled, Role of Apollon in Human Melanoma Resistance to Antitumor Agents That Activate the Intrinsic or the Extrinsic Apoptosis Pathways
Open the PDF for Role of Apollon in Human Melanoma Resistance to Antitumor Agents That Activate the Intrinsic or the Extrinsic Apoptosis Pathways in another window
Includes: Supplementary data
Journal Articles

Bevacizumab plus Fotemustine as First-line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis Factors

Free
Michele Del Vecchio, Roberta Mortarini, Stefania Canova, Lorenza Di Guardo, Nicola Pimpinelli, Mario R. Sertoli, Davide Bedognetti, Paola Queirolo, Paola Morosini, Tania Perrone, Emilio Bajetta, Andrea Anichini
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (23): 5862–5872.
https://doi.org/10.1158/1078-0432.CCR-10-2363
Published: 06 December 2010
View article titled, Bevacizumab plus Fotemustine as First-line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis Factors
Open the PDF for Bevacizumab plus Fotemustine as First-line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis Factors in another window
Includes: Supplementary data
Journal Articles

Immunotherapy of Metastatic Melanoma Using Genetically Engineered GD2-Specific T cells

Free
Eric Yvon, Michele Del Vecchio, Barbara Savoldo, Valentina Hoyos, Aurélie Dutour, Andrea Anichini, Gianpietro Dotti, Malcolm K. Brenner
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (18): 5852–5860.
https://doi.org/10.1158/1078-0432.CCR-08-3163
Published: 14 September 2009
View article titled, Immunotherapy of Metastatic Melanoma Using Genetically Engineered GD2-Specific T cells
Open the PDF for Immunotherapy of Metastatic Melanoma Using Genetically Engineered GD2-Specific T cells in another window
Includes: Supplementary data
Journal Articles

Impaired STAT Phosphorylation in T Cells from Melanoma Patients in Response to IL-2: Association with Clinical Stage

Free
Roberta Mortarini, Claudia Vegetti, Alessandra Molla, Flavio Arienti, Fernando Ravagnani, Andrea Maurichi, Roberto Patuzzo, Mario Santinami, Andrea Anichini
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (12): 4085–4094.
https://doi.org/10.1158/1078-0432.CCR-08-3323
Published: 15 June 2009
View article titled, Impaired STAT Phosphorylation in T Cells from Melanoma Patients in Response to IL-2: Association with Clinical Stage
Open the PDF for Impaired STAT Phosphorylation in T Cells from Melanoma Patients in Response to IL-2: Association with Clinical Stage in another window
Includes: Supplementary data
Journal Articles

Interleukin-12: Biological Properties and Clinical Application

Free
Michele Del Vecchio, Emilio Bajetta, Stefania Canova, Michael T. Lotze, Amy Wesa, Giorgio Parmiani, Andrea Anichini
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (16): 4677–4685.
https://doi.org/10.1158/1078-0432.CCR-07-0776
Published: 15 August 2007
View article titled, Interleukin-12: Biological Properties and Clinical Application
Open the PDF for Interleukin-12: Biological Properties and Clinical Application in another window
Journal Articles

Unique Tumor Antigens: Evidence for Immune Control of Genome Integrity and Immunogenic Targets for T Cell–Mediated Patient-Specific Immunotherapy

Free
Marialuisa Sensi, Andrea Anichini
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (17): 5023–5032.
https://doi.org/10.1158/1078-0432.CCR-05-2682
Published: 01 September 2006
View article titled, Unique Tumor Antigens: Evidence for Immune Control of Genome Integrity and Immunogenic Targets for T Cell–Mediated Patient-Specific Immunotherapy
Open the PDF for Unique Tumor Antigens: Evidence for Immune Control of Genome Integrity and Immunogenic Targets for T Cell–Mediated Patient-Specific Immunotherapy in another window
Journal Articles

Boosting T Cell-Mediated Immunity to Tyrosinase by Vaccinia Virus-Transduced, CD34+-Derived Dendritic Cell Vaccination: A Phase I Trial in Metastatic Melanoma

Free
Massimo Di Nicola, Carmelo Carlo-Stella, Roberta Mortarini, Paola Baldassari, Anna Guidetti, Gian Francesco Gallino, Michele Del Vecchio, Fernando Ravagnani, Michele Magni, Paul Chaplin, Natale Cascinelli, Giorgio Parmiani, Alessandro M. Gianni, Andrea Anichini
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (16): 5381–5390.
https://doi.org/10.1158/1078-0432.CCR-04-0602
Published: 24 August 2004
View article titled, Boosting T Cell-Mediated Immunity to Tyrosinase by Vaccinia Virus-Transduced, CD34+-Derived Dendritic Cell Vaccination: A Phase I Trial in Metastatic Melanoma
Open the PDF for Boosting T Cell-Mediated Immunity to Tyrosinase by Vaccinia Virus-Transduced, CD34+-Derived Dendritic Cell Vaccination: A Phase I Trial in Metastatic Melanoma in another window